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Clinical Question:  
Is avoiding or withdrawing steroids better or worse than continuing to use steroids for 
immunosuppression after liver transplantation?  
   
Bottom Line:  
There is uncertainty based on low to very low-quality evidence that avoiding or withdrawing 
steroids after liver transplantation affects mortality, graft loss, or infection rates. There is low-
quality evidence that avoiding or withdrawing steroids among liver transplant recipients 
reduces hypertension, diabetes mellitus and total serum cholesterol values. However, avoiding 
or withdrawingsteroids also increases acute rejection, steroid-resistant rejection and creatinine 
values.  
   
Evidence Profile  
No. of trials: 17a  
No. of randomized clinical trials: 17a  
Study years: 1998 to 2013  
No. of participants: 1347a  
Men: 73%b    Women:  27%b  
Race/ethnicity: Not reported  
Age, mean (range): 50 (42-58) yearsc  
Settings: Outpatient or inpatient transplant centers  
Countries: United States (n=2), China (n=3), Germany (n=1), Italy (n=5), Belgium (n=1), Spain (n=2), 
France (n=1), Czech Republic (n=1)  
Intervention: Avoidance or withdrawal of steroids for immunosuppression  
Comparison: Steroid-containing immunosuppression regimen  
Primary outcomes:  
 All-cause mortality  
 Graft loss including death  
 Acute rejection  
 Infection  
Secondary outcomes:  
 Chronic and steroid-resistant rejection  
 Cardiometabolic complications: diabetes mellitus, hypertension, hyperlipidemia  
 Hepatitis C virus (HCV) recurrence  
 Malignancy and post-transplantation lymphoproliferative disorder (PTLD)  
 Renal functiond  
 De novo autoimmune hepatitis  
 Health-related quality of life  
Prespecified subgroup analyses:  
 Different immunosuppressive agents  
 Co-interventions  
 Duration of treatment with steroids  
 Trials before the year 2000 compared to trials in and after year 2000  
Follow-up: 13 to 108 months  
a 1 trial of the 17 was published only in abstract form and thus only 16 trials had data available on a total of 1347 participants for meta-analysis.  
b Sex ratio only reported in 12 of 17 trials  
c Age only reported in 14 of 17 trials  
d Renal failure requiring dialysis, renal insufficiency, estimated glomerular filtration rate, serum creatinine  
   
Introduction 
Liver transplant recipients must take life-long immunosuppressive medication to prevent organ 
allograft rejection.  Currently available oral immunosuppressive agents include calcineurin 
inhibitors (e.g., cyclosporine, tacrolimus), antiproliferative agents (e.g., azathioprine, 
mycophenolate mofetil), mammalian target of rapamycin inhibitors (e.g., sirolimus, 
everolimus), induction agents (e.g., rabbit antithymocyte globulin, basiliximab, etc.) and 
glucocorticosteroids (e.g., prednisone). Historically, steroids have formed the backbone of 
immunosuppressive regimens after liver transplantation.  However, advancements in 
immunosuppression over the past 20 years have led many transplant centers to adopt steroid-
sparing immunosuppression protocols. Long-term immunosuppression, and in particular steroid 
use, carries with it substantial adverse effects including increasing risk of infection, bone loss 
and cardiometabolic diseases (e.g., obesity, hypertension, diabetes, and hyperlipidemia) .1 In 
fact, cardiovascular diseases are the leading cause of morbidity and mortality after liver 
transplantation.2,3 Thus, clinicians must aim to maximize the benefit of immunosuppressive 
agents to prevent rejection while minimizing their adverse effects.  This article summarizes 
a recent 2018 Cochrane review4 assessing the effects of steroid-minimization or 
avoidance among liver transplant recipients compared to steroid-containing 
immunosuppression protocols on mortality, graft loss, rejection and infection in addition to a 
variety of secondary cardiometabolic outcomes.   
 
Summary of Findings 
The authors identified 17 randomized clinical trials, but only 16 had available data for meta-
analysis for a total of 1347 participants performed between 1998 and 2013.  Most (10 of 16) 
trials assessed complete postoperative steroid avoidance (excluding intra-operative use or 
treatment of acute rejection) versus short-term steroids (n=782). The remaining 6 trials 
assessed short-term steroids versus long-term steroids (n=565). One study assessed complete 
postoperative steroid withdrawal but could not be incorporated into quantitative analysis since 
it was only published in abstract form and did not report the number of participants allocated 
to each arm. There was substantial heterogeneity between duration of steroid use in the 
steroid-containing arm of each included trial. Steroid administration was reported as 64 days 
(n=1), three months (n=7), three to six months (n=1), six months (n=2), nine months (n=1), 25 
months (n=1), indefinitely (n=2) and not reported at all (n=1).  Five trials began prior to 
2000, and the remaining 11 trials were published from 2000 onwards. All trials used 
a concomitant calcineurin inhibitor (tacrolimus (n=5), cyclosporine (n=11)). Seven trials used an 
antiproliferative agent and nine trials used induction therapy (rabbit antithymocyte globulin 
(n=2), basiliximab (n=5) and daclizumab (n=1)). Most (12 of 16) trials were single center 
studies, and all included an adult-only, predominantly male (73%) population. Follow-up for all 
endpoints ranged from 13 to 108 months. 
Low to very low-quality evidence suggests that there is uncertainty of effect between steroid 
avoidance or withdrawal compared to steroid-containing immunosuppression for mortality 
(19% steroid-free versus 17% steroid-containing; RR 1.15, 95% CI 0.93-1.44), graft loss including 
death (19% steroid-free versus 15% steroid-containing; RR 1.15, 95% CI 0.90-1.46), or infection 
(31% steroid-free versus 36% steroid-containing; RR 0.88, 95% CI 0.73-1.05; Table 1) among 
liver transplant recipients. Acute rejection (22% steroid-free versus 17% steroid-containing; RR 
1.33, 95% CI 1.08-1.64; low-quality evidence) and steroid-resistant rejection (5% steroid-free 
versus 3% steroid-containing; 2.14, 95% CI 1.13-4.02; very low-quality evidence) were more 
frequent among recipients in whom steroid-avoidance or withdrawal was used compared to 
steroid-containing immunosuppressive regimens. Among 4 trials with 309 
participants reporting renal function outcomes, creatinine levels were higher when steroid-
avoidance or withdrawal was compared to steroid-containing immunosuppression (mean 
difference (MD) 0.11 mg/dL, 95% 0.07-0.16, very low-quality evidence).  On the other hand, 
diabetes (21% steroid-free versus 26% steroid-containing; RR 0.88, 95% CI, 0.66-0.99; low-
quality evidence) and hypertension (29% steroid-free versus 38% steroid-containing; RR 0.76, 
95% CI 0.65-0.90, low-quality evidence) were less frequent in the steroid-avoidance or 
withdrawal groups compared to steroid-containing groups. Serum total cholesterol was 
also lower in steroid-avoidance or withdrawal compared with steroid-containing regimens (MD 
-18.49 mg/dL, 95% CI -22.02 to -14.96, very low-quality evidence). There 
is uncertainty surrounding benefits or harms across the remaining secondary outcomes 
assessed in this review based on low to very low-quality evidence (Table 1).  
 
Discussion 
Among 16 randomized clinical trials in 1,347 liver transplant recipients, there is uncertainty 
of benefit or harm for steroid avoidance or withdrawal versus steroid continuation on the 
primary outcomes of mortality, graft loss including death or infection rates after liver 
transplantation.  Steroid avoidance or withdrawal was associated 
with lower hypertension, diabetes and serum cholesterol.  These benefits are offset 
by higher acute rejection, steroid-resistance rejection and raised serum creatinine compared to 
steroid-containing immunosuppression regimens.  There is uncertainty of benefit or harm 
for other outcomes of interest including chronic rejection, cytomegalovirus infection, hepatitis 
C recurrence, malignancy, post-transplant lymphoproliferative disorder, renal insufficiency, 
hyperlipidemia, cholesterol or hypercholesterolemia. The overall quality of evidence was low in 
this review thus tempering the clinical implications of these findings. 
  
Limitations 
Most trials were small with a high risk of bias across at least one domain, which lowers the 
quality of evidence. One trial was terminated early due to a higher rate of rejection within the 
steroid-free arm which may exaggerate the effect as truncated trials are known to demonstrate 
more extreme intervention effects.6 There is uncertainty of the benefits and harms of steroid 
avoidance or withdrawal versus steroid-containing immunosuppressive regimens among liver 
transplant recipients. 
  
Heterogeneity in the duration and dosing regimen for steroids between each study also adds to 
uncertainty. There may be an optimum, short duration of steroid administration with which 
acute rejection in the early post-transplant phase can be prevented without significant impact 
on cardiometabolic adverse events. There may also be an opportunity for stratified 
immunosuppression with those considered to be low-risk of rejection or high-risk of 
cardiometabolic disease being offered steroid-free immunosuppression. 
  
The studies in this meta-analysis excluded retransplantation, multi-organ transplantation and 
pediatric participants. 
 
Areas in Need of Future Study 
High-quality, adequately powered trials using contemporary immunosuppression protocols, 
varied duration of steroid administration based on current practice patterns and longer periods 
of follow-up are needed to evaluate the safety and efficacy of steroid avoidance or withdrawal 
in liver transplant recipients. It may be of benefit to construct a high-quality three-arm trial 
comparing complete postoperative steroid avoidance, short-term steroids, and long-term 
steroids. As of May 26, 2020, there is no registered clinical trial that meets these criteria. Such a 
trial will require multi-center, and possibly, international collaboration in order to obtain 
adequate sample size across each randomization strata.  Limited funding is a major potential 
barrier.  Thus, there is an urgent need for joint collaboration among industry, academia, 
regulatory, government and transplantation organizations to patner together to conduct 
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Table 1. Summary of Findings for the Effect of Steroid-Withdrawal or Steroid-
Avoidance Versus Continuation of Steroids in Liver Transplant Recipients 
Outcomea 
Anticipated Absolute Effects 
(No. of Cases per 
1000 population)b 
Relative Effect, RR or 
Mean Difference, 












All-cause mortality 166 191 (154-239) 1.15 (0.93-1.44) 1323 15 Lowd,e 
Graft loss including 
death 
175 203 (159-259) 1.15 (0.90-1.46) 1002 11 Lowd,e 
Acute rejection 173 230 (187-283) 1.33 (1.08-1.64) 1347 16 Lowd,e 
Infection 359 316 (262-377) 0.88 (0.73-1.05) 778 8 Very Lowd,e,f 
Chronic rejection 30 33 (17-64) 1.08 (0.56-2.10) 974 9 Very lowd,e,f 
Steroid-resistant 
rejection 
25 54 (29-101) 2.14 (1.13-4.02) 1020 10 Very lowd,e,f 
Diabetes Mellitus 261 212 (172-259) 0.81 (0.66-0.99)* 1185 12 Lowd,f 
CMV infection 95 70 (46-110) 0.74 (0.48-1.16) 786 7 Lowd,e 
HCV recurrence 661 681 (608-760) 1.03 (0.92-1.15) 447 10 Very lowd,e,f 
Malignancy 26 13 (4-45) 0.52 (0.16-1.74) 528 3 Very lowd,e,f 
PTLD 6 14 (2-95) 2.39 (0.36-15.95) 330 2 Very lowd,e,f 
Renal insufficiency 333 310 (243-397) 0.93 (0.73-1.19) 447 4 Very lowd,e,f 









0.11 (0.07-0.16)* 309 4 Very lowd,e,f 
Hypertension 378 288 (246-341) 0.76 (0.65-0.90) 1098 10 Lowd,f 
Hyperlipidemia 89 67 (34-131) 0.75 (0.38-1.48) 400 4 Very lowd,e,f 
Hypercholesterolemia 212 119 (68-212) 0.56 (0.31-1.00) 266 2 Very lowd,e,f 











556 5 Very lowd,e,f 
Abbreviations: CMV, cytomegalovirus; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HCV, hepatitis C 
virus; MD, mean difference; No., number; PTLD, post-transplant lymphoproliferative disorder; RCTs, randomized clinical trials; RR, risk ratio. 
*Fixed effects model, random-effects model for diabetes RR (95% CI)=0.82 (0.64-1.07) and for creatinine MD (95% CI)=0.01 (-0.21-0.23) mg/dL 
a All outcomes were assessed at latest follow up (range 13 months to 108 months) 
b The risk in the intervention group is based on the assumed risk in the comparison group, which is calculated from the control arm of the meta-
analysis and the relative effect of the intervention. 
c The GRADE Working Group grades of evidence5 were as follows: high quality (the true effect lies close to that of the estimate of the effect), 
moderate quality (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different), low 
quality (the true effect may be substantially different from the estimate of the effect), and very low quality (the true effect is likely to be 
substantially different from the estimate of effect). 
d Downgraded because of risk of bias 
e Downgraded because of imprecision. 
f Downgraded because of heterogeneity between subgroups; avoidance versus withdrawal. 
 
